Checked.be
Active
BE 0759.718.351Private limited company
DOKTER MEUWISSEN
Egstraat 15 ·3920 Lommel, Belgium· 5 yrs active
Sector: Specialist medical practice
(86220)
Conclusion
DOKTER MEUWISSEN has been active since 2020 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €185k and a net result of €-14k. Equity remains stable across the filed fiscal years (±2.1% per year). Its solvency ranks better than 95% of 2244 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Based on the State Gazette, CBE and 5 annual accounts.
Key figures
| Equity | €185k |
| Net result | €-14k |
| Better than sector | 95% |
| Active | 5 yrs |
Financial profile
65
/ 100
Strong profile, led by solvency.
All 5 axes are computed from data Checked has read.
Health
78
Profitability
0
Solvency
100
Growth
52
Stability
94
Bankruptcy probability (12 mo)
Risk Assessment
0 / 100
Low riskTrust signals
More than 3 years active
Founded in 2020, past the statistically most fragile first 3 years.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Checked score
78
/ 100
Excellent
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
Indicative credit limit
€14k
estimate, not credit advice
Score history
93
2021
100
2022
68
2023
52
2024
78
2025
purely financial, excl. current insolvency signals
Score components
Liquidity
Current ratio 124.13 (≥ 1.5)
+10
Quick ratio
Quick ratio 124.13 (≥ 1.0)
+5
Leverage
Debt/equity 0.01 (< 1.0)
+10
Profitability
Negatieve ROE -8%
-10
Interest coverage
Interest coverage 24.7× (≥ 3×)
+8
Profit trend
Net profit up YoY
+5
Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.
Financial overview
Annual accounts filed on 31-08-2026 with the NBB · fiscal year 2025 · abbreviated schema
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
stable
Equity: stable across 5 fiscal years (±2.1%/year).
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
Sector comparison
Fiscal year 2025 · NACE 86, Human health activities · compared within the same schema type (abbreviated schema)
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 99.3% | 59.8% | |
| Net result | €-14k | €121k | |
| Equity | €185k | €395k | |
| Gross operating margin | €4k | €301k | |
| Staff costs | €2k | €111k |
€2k
-
21-25
€-14k
+83.0%
21-25
€5k
-
21-25
€186k
-7.1%
21-25
€185k
-7.1%
21-25
€151k
+0.1%
21-25
€2k
+9.1%
21-25
€214
-6.6%
21-25
€1k
-11.0%
21-25
€1k
-11.0%
21-25
124.13
+12.4%
21-25
124.13
+12.4%
21-25
99.3%
0.0%
21-25
0.01
-4.2%
21-25
-7.6%
+81.7%
21-25
-7.6%
+81.7%
21-25
24.71
-
21-25
Figures by fiscal year and ratios
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Deposit | abbreviated schema | micro schema | micro schema | micro schema | micro schema |
| Revenue | - | - | - | - | - |
| EBITDA | €2k | €-63k | €94k | €159k | €127k |
| Net profit | €-14k | €-83k | €59k | €119k | €99k |
| Cash flow | €5k | €-63k | €79k | €127k | €99k |
| Staff costs | €2k | €2k | €2k | €2k | €2k |
| Income taxes | €214 | €229 | €16k | €32k | €28k |
| Dividends | - | - | - | - | - |
| Total assets | €186k | €200k | €282k | €235k | €131k |
| Equity | €185k | €199k | €282k | €223k | €104k |
| Debt | €1k | €1k | - | €13k | €28k |
| of which ≤ 1y | €1k | €1k | - | €13k | €28k |
| of which > 1y | - | - | - | - | - |
| Working capital | €151k | €150k | - | €137k | €103k |
| Employees (FTE) | - | - | - | - | - |
Note: these years are not on the same basis. The filed schemas differ (abbreviated schema, micro schema), so the columns are not directly comparable.
Ratios (computed)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Current ratio | 124.13 | 110.42 | - | 11.90 | 4.71 |
| Quick ratio | 124.13 | 110.42 | - | 11.90 | 4.71 |
| Working capital ratio | 81.0% | 75.1% | - | 58.1% | 78.0% |
| Solvency | 99.3% | 99.3% | 100.0% | 94.7% | 78.9% |
| Debt / equity | 0.01 | 0.01 | - | 0.06 | 0.27 |
| Long-term debt ratio | - | - | - | - | - |
| Interest coverage | 24.71 | -850.05 | 1331.07 | 2276.05 | 1895.86 |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| ROA | -7.6% | -41.3% | 21.0% | 50.5% | 75.1% |
| ROE | -7.6% | -41.6% | 21.0% | 53.4% | 95.2% |
| EBITDA margin | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days inventory (DSI) | - | - | - | - | - |
Balance-sheet composition 2025
Full annual accounts (21 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
| Line item | Code | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Balance sheet, Assets | ||||||
| TOTAL ASSETS | 20/58 | €186k | €200k | €282k | €235k | €131k |
| Fixed assets | 21/28 | €34k | €48k | €68k | €86k | €1k |
| Tangible fixed assets | 22/27 | €34k | €48k | €68k | €86k | €1k |
| Current assets | 29/58 | €152k | €152k | €213k | €149k | €130k |
| Amounts receivable within one year | 40/41 | €103k | €2k | €24k | - | €2k |
| Cash & bank | 54/58 | €49k | €149k | €189k | €147k | €126k |
| Balance sheet, Equity & liabilities | ||||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €186k | €200k | €282k | €235k | €131k |
| Equity | 10/15 | €185k | €199k | €282k | €223k | €104k |
| Contributions / capital | 10/11 | €5k | €5k | €5k | €5k | €5k |
| Accumulated profits (losses) | 14 | €180k | €194k | €277k | €218k | €99k |
| Amounts payable | 17/49 | €1k | €1k | - | €13k | €28k |
| Amounts payable within one year | 42/48 | €1k | €1k | - | €13k | €28k |
| Trade debts payable within one year | 44 | €781 | €1k | - | - | - |
| Income statement | ||||||
| Gross operating margin | 9900 | €4k | €-61k | €96k | €161k | €129k |
| Operating result | 9901 | €-17k | €-83k | €75k | €151k | €127k |
| Financial income | 75 | €3k | €143 | - | - | €64 |
| Financial charges | 65 | €78 | €74 | €71 | €70 | €67 |
| Result before taxes | 9903 | €-14k | €-82k | €75k | €151k | €127k |
| Income taxes | 67/77 | €214 | €229 | €16k | €32k | €28k |
| Net result for the period | 9904 | €-14k | €-83k | €59k | €119k | €99k |
| Result to be appropriated | 9905 | €-14k | €-83k | €59k | €119k | €99k |
Legal Structure
| NACE primary | Specialist medical practice(86220) |
| Legal form | Private limited company(610) |
| Incorporation | 11-12-2020 |
| Status | Active |
| Postal code | 3920 |
Establishment units
DOKTER MEUWISSEN
since 20202.311.109.726
Real-estate footprint
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 72342A1205/00E000 | Flanders | 2,066 m² | 1 · 62 m² | 3.3 m · 1 fl. |
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates
Next filing, fiscal year 2026, expected by
2026
31-08
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema · 31 days late
2025
05-07
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
31-12
Financial
Weakest financial yearnet €-83k ▼240%
Net result drops to €-83k, the lowest in the series; recovery starts the following year.
17-07
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
01-07
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
2022
31-12
Financial
Highest result since 2021net €119k ▲20.2%
Operating result €151k, net result €119k, both a record.
31-12
Financial
Liquidity triplescurrent ratio 11.90
Current ratio from 4.71 to 11.90; short-term debt falls from €28k to €13k.
31-12
Financial
Equity above €200kEq €223k ▲114%
2 profitable years in a row build equity to €223k.
18-08
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema · 18 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Belgian State Gazette reading coverage
We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Credit advice
Company registry (CBE)
Activities
Specialist medical practice86220
Names & trade names
| Legal nameNL | DOKTER MEUWISSEN |
Similar companies
DOCTEUR CIUTEA MIRELA CARDIOLOGUE
BE 0735.652.750 · Liège
CENTRE DE CARDIOLOGIE VIVEGNIS
BE 0698.983.978 · Liège
Dr. Marlies Van de Voorde, pediatrie
BE 0795.201.050 · Gent
CARDIO PH HENRY
BE 0897.594.844 · Namur
Dr V Vandermotte Cardiologie
BE 0764.674.754 · Hove